Drug Trial Radar · NCT03915964
A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis
Last checked: Nov 19, 2026Latest source record: Jun 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,659
Actual
Start
Apr 25, 2019
Primary completion
May 28, 2025
Study completion May 28, 2025
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- Collaborators
- Incyte Corporation
- First posted
- Apr 16, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis.
Conditions
- Rheumatoid Arthritis
Interventions
BaricitinibDrug
Administered orally.
TNF InhibitorDrug
Administered subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Event of Venous Thromboembolism (VTE) [Combined Baricitinib Dose Versus TNF Inhibitor]Time frame: From the first dose of study treatment up to 30 days after the last dose or the last study visit, whichever occurs first (approximately up to 6.1 years for JAJA and 5.3 years for JAJD participants)
Locations
261 sites in 24 countries. Site status is shown where the registry gives one.
Arizona Arthritis & Rheumatology Research, PLLC
Flagstaff, Arizona
Arthrocare, Arthritiscare & Research PC
Gilbert, Arizona
Arizona Arthritis & Rheumatology Research, PLLC
Glendale, Arizona
Arizona Arthritis & Rheumatology Research, PLLC
Mesa, Arizona
Hope Research Institute
Peoria, Arizona
Hope Research Institute
Phoenix, Arizona
Arizona Arthritis & Rheumatology Research, PLLC
Tucson, Arizona
Medvin Clinical Research - Covina
Covina, California
St Joseph Heritage Healthcare
Fullerton, California
Christine Thai, MD
Huntington Beach, California
Private Practice - Dr. Christine J. Leehealey
Irvine, California
Desert Medical Advances
Rancho Mirage, California
Rheumatology Center of San Diego
San Diego, California
East Bay Rheumatology Medical Group, Inc
San Leandro, California
Dan La, MD Inc
Tujunga, California
Robin K. Dore MD, Inc
Tustin, California
Inland Rheumatology & Osteoporosis Medical Group
Upland, California
Medvin Clinical Research - Weidmann
Van Nuys, California
Medvin Clinical Research - Whittier
Whittier, California
Stamford Therapeutics Consortium
Stamford, Connecticut
Rheumatology Associates of South Florida
Boca Raton, Florida
Suncoast Research Group
Miami, Florida
New Horizon Research Center
Miami, Florida
Suncoast Clinical Research, Inc.
New Port Richey, Florida
IRIS Research and Development, LLC
Plantation, Florida
Qps-Mra, Llc
South Miami, Florida
ForCare Clinical Research
Tampa, Florida
Arthritis & Rheumatology of Georgia
Atlanta, Georgia
Arthritis Center of North Georgia
Gainesville, Georgia
St. Luke's Intermountain Research Center
Boise, Idaho
Great Lakes Clinical Trials
Chicago, Illinois
Qualmedica Research, LLC
Evansville, Indiana
Alliance for Multispecialty Research, LLC
Wichita, Kansas
Center for Arthritis and Osteoporosis
Elizabethtown, Kentucky
Accurate Clinical Research
Lake Charles, Louisiana
The Center for Rheumatology and Bone Research
Wheaton, Maryland
NECCR PrimaCare Research
Fall River, Massachusetts
University of Michigan
Brighton, Michigan
West Michigan Rheumatology
Grand Rapids, Michigan
Advanced Rheumatology, PC
Okemos, Michigan
Showing 40 of 261 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.